For tumors with low SLFN11 expression, systematically evaluate the efficacy of the combination regimens of ATR inhibitors, ATM inhibitors, CHK1 inhibitors, and WEE1 inhibitors with standard chemotherapy in different cancers. This evidence concerns the gene ATR and cancer.